Study identifies new marker to find patients with advanced prostate cancer more likely to benefit from combination immunotherapy | Newswise

Patients with metastatic castration-resistant prostate cancer who do not benefit from chemotherapy need more effective treatment options Phase 2 CheckMate 650 trial found ipilimumab plus nivolumab durable and clinically meaningful responses in a subset of patients Through capabilities of the James P. Allison Institute, researchers identified a signature associated with prolonged overall survival, helping to find those most likely to benefit

Study identifies new marker to find patients with advanced prostate cancer more likely to benefit from combination immunotherapy | Newswise. Patients with metastatic castration-resistant prostate cancer who do not benefit from chemotherapy need more effective treatment options Phase 2 CheckMate 650 trial found ipilimumab plus nivolumab durable and clinically meaningful responses in a subset of patients Through capabilities of the James P. Allison Institute, researchers identified a signature associated with prolonged overall survival, helping to find those most likely to benefit HOUSTON, MAY 20, 2026 ― Researchers with the James P. Allison InstituteTM at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with metastatic castration-resistant prosta...